Oxford University and Ellison Institute link for AI vaccine research
The programme seeks to combine Oxford's strengths in vaccine development with EIT's AI tech advancements.
Artificial Intelligence
AI psychosis sees users ‘co-creating delusions with technology’ – expert
AI is improving idiopathic pulmonary fibrosis care
Five lessons from biopharma companies’ data transformation journeys
AI in drug discovery: from hypothetical to reality
Lisata collaborates with GATC Health on drug development
Juvenescence enhances AI drug discovery with Ro5 acquisition
Pharma’s AI prospects get nudged into the future with EU’s AI act
